AstraZeneca ends R&D in India


Pharmaceutical firm AstraZeneca (AZ) is quitting its R&D site in Bangalore, India. The closure means 168 employees, researching neglected tropical diseases, tuberculosis (TB) and malaria, will lose their jobs as AZ drops its early-stage research into these areas.

The company will retain more advanced projects, such as AZD5847, which is in Phase II trials against TB. It will also outsource the site’s current product development functions, or transfer them to Macclesfield, UK. However, AZ confirmed it will maintain access to its compound library for open innovation projects in neglected diseases.

The closure is part of AZs ongoing restructuring programme, which began last year, will cost a total of 1600 jobs worldwide and see the company’s main UK R&D activities move from Alderley Park to Cambridge. After the closure, AZ will have just over 1000 staff in India, across manufacturing, sales and marketing roles.


Related Content

Global AstraZeneca restructuring will cost 1600 jobs

19 March 2013 Business

news image

Firm will focus drug development efforts in three strategic R&D centres in the UK, Sweden and the US

Generation next

29 January 2014 Educated Chemist

news image

AstraZeneca is investing in the future of drug discovery with its new graduate training scheme in pharma. Manisha Lalloo find...

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

Smart skin for prosthetic limbs senses heat and touch

12 December 2014 Research

news image

Ultra-thin plastic skin can bend and flex without affecting the skin's ability to detect stimuli

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint